Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 4/20 | 0.32 |
| ▸ | STK10 | O94804 | 2/20 | 0.31 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | GSK3A | P49840 | 1/20 | 0.30 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15036504 | 0.90 | IDO1 (0.35) | PTGS1PTGS2IDO1TDO2GSK3B | |
| SCHEMBL16426672 | 0.75 | IDO1 (0.42) | PTGS1PTGS2IDO1TDO2GSK3B | |
| SCHEMBL15020065 | 0.75 | DNM1 (0.42) | PTGS1PTGS2IDO1TDO2GSK3B | |
| SCHEMBL15039580 | 0.75 | DNM1 (0.42) | PTGS1PTGS2IDO1TDO2GSK3B | |
| SCHEMBL15020067 | 0.75 | DNM1 (0.42) | PTGS1PTGS2IDO1TDO2GSK3B | |
| SCHEMBL15020486 | 0.74 | DNM1 (0.38) | PTGS1PTGS2IDO1TDO2GSK3B | |
| SCHEMBL15020488 | 0.74 | DNM1 (0.38) | PTGS1PTGS2IDO1TDO2GSK3B | |
| SCHEMBL16426675 | 0.74 | DNM1 (0.38) | PTGS1PTGS2IDO1TDO2GSK3B | |
| SCHEMBL16426665 | 0.73 | RAB9A (0.34) | MAPT | |
| SCHEMBL15020051 | 0.73 | ALDH1A1 (0.33) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9554977-B2 | Triaromatic azomethine direct dyes, dye composition comprising at least one such dye, method of implementation and use | L'OREAL (FR) | 2017-01-31 | — | — | US | disclosed |
| US-20150320660-A1 | TRIAROMATIC AZOMETHINE DIRECT DYES, DYE COMPOSITION COMPRISING AT LEAST ONE SUCH DYE, METHOD OF IMPLEMENTATION AND USE | L'OREAL (FR) | 2015-11-12 | — | — | US | disclosed |
| WO-2013087768-A1 | TRIAROMATIC AZOMETHINE DIRECT DYES, DYE COMPOSITION COMPRISING AT LEAST ONE SUCH DYE, METHOD OF IMPLEMENTATION AND USE | L'OREAL (FR) | 2013-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150320660-A1 | TRIAROMATIC AZOMETHINE DIRECT DYES, DYE COMPOSITION COMPRISING AT LEAST ONE SUCH DYE, METHOD OF IMPLEMENTATION AND USE | KRT18, MKI67, CDC73 | PTGS1 2413/4885PTGS2 3236/4885IDO1 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.